amifostine anhydrous has been researched along with Hypercalcemia in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Hypercalcemia: Abnormally high level of calcium in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The rat Walker carcinosarcoma 256 is an animal model for humoral hypercalcaemia of malignancy (HHM)." | 1.28 | Relative role of bone and kidney in the hypercalcaemia associated with the rat Walker carcinosarcoma 256. ( Esbrit, P; Hurtado, J; Rapado, A, 1991) |
| "PTHrP-(1-34) (90 pmol/h) stimulated bone resorption as evaluated by an increment in fasting urinary Ca excretion." | 1.28 | Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats. ( Bonjour, JP; Caverzasio, J; Chapuy, MC; Martin, TJ; Rizzoli, R, 1989) |
| "The Rice-500 Leydig cell tumor (LCT) in Fischer rats is a model of humoral hypercalcemia of malignancy (HHM)." | 1.27 | Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721. ( Bonjour, JP; Caverzasio, J; Hirschel-Scholz, S; Rizzoli, R, 1986) |
| "In vitro bone resorption assays utilizing fetal rat long bones in organ culture showed complementary results." | 1.27 | In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat. ( Fallon, M; Goldfarb, S; Walker, ST; Weiss, J, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (84.62) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Rourke, N | 1 |
| McCloskey, E | 1 |
| Kanis, J | 1 |
| Hurtado, J | 1 |
| Esbrit, P | 1 |
| Rapado, A | 1 |
| Rizzoli, R | 4 |
| Bonjour, JP | 6 |
| Caverzasio, J | 4 |
| Chapuy, MC | 1 |
| Martin, TJ | 1 |
| Lefebvre, J | 1 |
| Hirschel-Scholz, S | 4 |
| Glover, DJ | 1 |
| Shaw, L | 1 |
| Glick, JH | 1 |
| Slatopolsky, E | 1 |
| Weiler, C | 1 |
| Attie, M | 1 |
| Goldfarb, S | 2 |
| Jung, A | 1 |
| Fischer, JA | 1 |
| Trechsel, U | 1 |
| Warrell, RP | 1 |
| Weiss, J | 1 |
| Walker, ST | 1 |
| Fallon, M | 1 |
| Zingraff, J | 1 |
| Bourdeau, A | 1 |
| Clair, F | 1 |
| Kindermans, C | 1 |
| Buisson, C | 1 |
| Manganella, G | 1 |
| Sachs, C | 1 |
| Drüeke, T | 1 |
4 reviews available for amifostine anhydrous and Hypercalcemia
| Article | Year |
|---|---|
[PTH-like tumor peptide and malignant hypercalcemia].
Topics: Amifostine; Bone Resorption; Calcium; Humans; Hypercalcemia; Neoplasm Proteins; Neoplasms; Parathyro | 1989 |
Possibilities and limits of the medical treatment for primary hyperparathyroidism.
Topics: Amifostine; Humans; Hypercalcemia; Hyperparathyroidism; Parathyroid Hormone | 1989 |
Management of hypercalcemia in relation to pathophysiology.
Topics: Amifostine; Bone Resorption; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Organothiophosph | 1987 |
Mechanism of the hypocalcemic agent WR-2721 and its acute and chronic application in eu- and hyperparathyroidism.
Topics: Amifostine; Animals; Bone Resorption; Humans; Hypercalcemia; Hyperparathyroidism; Magnesium; Organot | 1986 |
9 other studies available for amifostine anhydrous and Hypercalcemia
| Article | Year |
|---|---|
WR-2721 and hypocalcemia.
Topics: Amifostine; Humans; Hypercalcemia; Neoplasms | 1994 |
Relative role of bone and kidney in the hypercalcaemia associated with the rat Walker carcinosarcoma 256.
Topics: Amifostine; Animals; Bone and Bones; Calcium; Carcinoma 256, Walker; Diphosphonates; Female; Hyperca | 1991 |
Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats.
Topics: Amifostine; Animals; Bone Resorption; Calcium; Hypercalcemia; Kidney; Magnesium; Male; Metabolic Cle | 1989 |
Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid.
Topics: Adenoma; Aged; Amifostine; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; H | 1985 |
Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma.
Topics: Amifostine; Calcium; Cyclic AMP; Female; Humans; Hypercalcemia; Middle Aged; Organothiophosphorus Co | 1985 |
Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
Topics: Absorption; Amifostine; Animals; Calcium; Cyclic AMP; Glomerular Filtration Rate; Hypercalcemia; Kid | 1986 |
New inhibitors of osteolysis: implications for hypercalcemia and bone metastases.
Topics: Amifostine; Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; | 1986 |
In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
Topics: Amifostine; Animals; Bone Resorption; Calcitriol; Carcinoma 256, Walker; Female; Glutathione; Hyperc | 1986 |
Hypocalcaemic effect of WR-2721, S-2 (3-aminopropylamino) ethyl-phosphorothioic acid in an anuric haemodialysis patient.
Topics: Amifostine; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; | 1987 |